Institution
Alzheimer Europe
Nonprofit•Luxembourg, Luxembourg•
About: Alzheimer Europe is a nonprofit organization based out in Luxembourg, Luxembourg. It is known for research contribution in the topics: Dementia & Health care. The organization has 18 authors who have published 73 publications receiving 4504 citations. The organization is also known as: Alzheimer Europe.
Papers
More filters
••
Karolinska Institutet1, Karolinska University Hospital2, Pasteur Institute3, University of Toulouse4, Wolfson Centre for Age-Related Diseases5, University of Cambridge6, University of New South Wales7, Pierre-and-Marie-Curie University8, La Trobe University9, Umeå University10, University of British Columbia11, University of Geneva12, Douglas Mental Health University Institute13, Alzheimer Europe14, University of Cologne15, German Center for Neurodegenerative Diseases16, London School of Economics and Political Science17, Radboud University Nijmegen18, Rockefeller University19, VU University Medical Center20, University of Southern California21, Brigham and Women's Hospital22, University of Copenhagen23, UCL Institute of Neurology24, University of Gothenburg25
TL;DR: This poster aims to demonstrate the efforts towards in-situ applicability of EMMARM, which aims to provide real-time information about the physical and cognitive properties of Alzheimer's disease and other dementias.
Abstract: Defeating Alzheimer's disease and other dementias : a priority for European science and society
1,215 citations
••
TL;DR: The first definition of palliative care in dementia based on evidence and consensus is provided, a framework to provide guidance for clinical practice, policy and research.
Abstract: Background: Dementia is a life-limiting disease without curative treatments. Patients and families may need palliative care specific to dementia. Aim: To define optimal palliative care in dementia. Methods: Five-round Delphi study. Based on literature, a core group of 12 experts from 6 countries drafted a set of core domains with salient recommendations for each domain. We invited 89 experts from 27 countries to evaluate these in a two-round online survey with feedback. Consensus was determined according to predefined criteria. The fourth round involved decisions by the core team, and the fifth involved input from the European Association for Palliative Care. Results: A total of 64 (72%) experts from 23 countries evaluated a set of 11 domains and 57 recommendations. There was immediate and full consensus on the following eight domains, including the recommendations: person-centred care, communication and shared decision-making; optimal treatment of symptoms and providing comfort (these two identified as central to care and research); setting care goals and advance planning; continuity of care; psychosocial and spiritual support; family care and involvement; education of the health care team; and societal and ethical issues. After revision, full consensus was additionally reached for prognostication and timely recognition of dying. Recommendations on nutrition and dehydration (avoiding overly aggressive, burdensome or futile treatment) and on dementia stages in relation to care goals (applicability of palliative care) achieved moderate consensus. Conclusion: We have provided the first definition of palliative care in dementia based on evidence and consensus, a framework to provide guidance for clinical practice, policy and research.
709 citations
••
TL;DR: This international guideline on dementia covers major aspects of diagnostic evaluation and treatment, with particular emphasis on the type of patient often referred to the specialist physician, and revised the recommendations for clinical diagnosis, blood tests, neuroimaging, electroencephalography, and cerebrospinal fluid analysis.
Abstract: The aim of this international guideline on dementia was to present a peer-reviewed evidence-based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists, and other specialist physicians responsible for the care of patients with dementia. It covers major aspects of diagnostic evaluation and treatment, with particular emphasis on the type of patient often referred to the specialist physician. The main focus is Alzheimer's disease, but many of the recommendations apply to dementia disorders in general. The task force working group considered and classified evidence from original research reports, meta-analysis, and systematic reviews, published before January 2006. The evidence was classified and consensus recommendations graded according to the EFNS guidance. Where there was a lack of evidence, but clear consensus, good practice points were provided. The recommendations for clinical diagnosis, blood tests, neuroimaging, electroencephalography (EEG), cerebrospinal fluid (CSF) analysis, genetic testing, tissue biopsy, disclosure of diagnosis, treatment of Alzheimer's disease, and counselling and support for caregivers were all revised when compared with the previous EFNS guideline. New recommendations were added for the treatment of vascular dementia, Parkinson's disease dementia, and dementia with Lewy bodies, for monitoring treatment, for treatment of behavioural and psychological symptoms in dementia, and for legal issues. The specialist physician plays an important role together with primary care physicians in the multidisciplinary dementia teams, which have been established throughout Europe. This guideline may contribute to the definition of the role of the specialist physician in providing dementia health care.
618 citations
••
University of Geneva1, University of Gothenburg2, Sahlgrenska University Hospital3, VU University Amsterdam4, Istituto Universitario Di Studi Superiori Di Pavia5, Stockholm County Council6, University Hospital of Lausanne7, University of Zurich8, Lund University9, University of Manchester10, Mayo Clinic11, University of Genoa12, European Association of Nuclear Medicine13, Karolinska University Hospital14, Alzheimer's Association15, University of Amsterdam16, Vita-Salute San Raffaele University17, Queen Mary University of London18, Beta19, University of Bern20, University of Brescia21, Geneva College22, University of Malta23, Alzheimer Europe24, University College London25, Stanford University26, University of Rostock27, German Center for Neurodegenerative Diseases28, Imperial College London29, Maastricht University30, St. Jude Children's Research Hospital31, Karolinska Institutet32
TL;DR: A strategic five-phase roadmap to foster the clinical validation of biomarkers in Alzheimer's disease, adapted from the approach for cancer biomarkers is developed.
Abstract: The diagnosis of Alzheimer's disease can be improved by the use of biological measures. Biomarkers of functional impairment, neuronal loss, and protein deposition that can be assessed by neuroimaging (ie, MRI and PET) or CSF analysis are increasingly being used to diagnose Alzheimer's disease in research studies and specialist clinical settings. However, the validation of the clinical usefulness of these biomarkers is incomplete, and that is hampering reimbursement for these tests by health insurance providers, their widespread clinical implementation, and improvements in quality of health care. We have developed a strategic five-phase roadmap to foster the clinical validation of biomarkers in Alzheimer's disease, adapted from the approach for cancer biomarkers. Sufficient evidence of analytical validity (phase 1 of a structured framework adapted from oncology) is available for all biomarkers, but their clinical validity (phases 2 and 3) and clinical utility (phases 4 and 5) are incomplete. To complete these phases, research priorities include the standardisation of the readout of these assays and thresholds for normality, the evaluation of their performance in detecting early disease, the development of diagnostic algorithms comprising combinations of biomarkers, and the development of clinical guidelines for the use of biomarkers in qualified memory clinics.
446 citations
••
TL;DR: Twenty-two measures across nine domains were recommended in order to improve the comparability of intervention studies in Europe and covered the domains of quality of life, mood, global function, behaviour and daily living skills.
Abstract: Psychosocial intervention makes a vital contribution to dementia care. However, the lack of consensus about which outcome measures to use to evaluate effectiveness prevents meaningful comparisons between different studies and interventions. This study used an iterative collaborative, evidence-based approach to identify the best of currently available outcome measures for European psychosocial intervention research. This included consensus workshops, a web-based pan-European consultation and a systematic literature review and a rigorous evaluation against agreed criteria looking at utility across Europe, feasibility and psychometric properties. For people with dementia the measures covered the domains of quality of life, mood, global function, behaviour and daily living skills. Family carer domains included mood and burden, which incorporated coping with behaviour and quality of life. The only specific staff domain identified was morale, but this included satisfaction and coping with behaviour. In conclusion twenty-two measures across nine domains were recommended in order to improve the comparability of intervention studies in Europe. Areas were identified where improved outcome measures for psychosocial intervention research studies are required.
353 citations
Authors
Showing all 18 results
Name | H-index | Papers | Citations |
---|---|---|---|
Keith A. Johnson | 120 | 798 | 51034 |
Jean Georges | 16 | 45 | 2603 |
Charles Scerri | 16 | 51 | 1129 |
Dianne Gove | 16 | 40 | 1376 |
Ana Diaz | 6 | 9 | 188 |
Ana Diaz-Ponce | 5 | 9 | 181 |
Anders Gustavsson | 3 | 3 | 60 |
Christophe Bintener | 3 | 4 | 42 |
Ana Maria Diaz Ponce | 2 | 3 | 6 |
Linus Jönsson | 2 | 2 | 23 |
H. von Lützau-Hohlbein | 2 | 2 | 29 |
M. O'connell | 1 | 1 | 3 |
M. O'connell | 1 | 1 | 326 |
Alan Jacques | 1 | 1 | 7 |
Jean-Jacques Georges | 1 | 1 | 25 |